| Literature DB >> 15977426 |
Andrew T Gewirtz1, Shanthi V Sitaraman.
Abstract
Isis is developing alicaforsen, an RNase H-dependent antisense inhibitor of intercellular adhesion molecule-1, for the potential treatment of ulcerative colitis. The therapy is currently undergoing phase II clinical trials.Entities:
Mesh：
Substances：
Year: 2005 PMID： 15977426
Source DB: PubMed Journal: Curr Opin Mol Ther ISSN： 1464-8431